
|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Surrounded
Author(s)Wayne Koberstein
}Drug costs continue to rise at an alarming rate. Two major reasons for the increasing costs are introductions of new drugs and direct-to-consumer advertising campaigns that have been effective in marketing expensive name brand drugs.}
Advertisement
Articles in this issue
almost 25 years ago
Research: New Horizonsalmost 25 years ago
Earnings: Tough Times Aheadalmost 25 years ago
Outbreak: Anthrax Alarmalmost 25 years ago
Patents: China on the Genome Mapalmost 25 years ago
Privacy, Pediatrics, and Policyalmost 25 years ago
Lilly's International Familyalmost 25 years ago
Update: Punishment and Reprievealmost 25 years ago
Shortage: Vaccine Worriesalmost 25 years ago
Gateway to JapanNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
FDA Announces Agency-Wide Deployment of Agentic AI Tools
4
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
5





